title: Immune status following alemtuzumab treatment in human CD52 transgenic mice.
abstract: Alemtuzumab is a monoclonal antibody against the CD52 antigen present at high levels on the surface of lymphocytes. While treatment of multiple sclerosis patients with alemtuzumab results in marked depletion of lymphocytes from the circulation, it has not been associated with a high incidence of serious infections. In a human CD52 transgenic mouse, alemtuzumab treatment showed minimal impact on the number and function of innate immune cells. A transient decrease in primary adaptive immune responses was observed post-alemtuzumab but there was little effect on memory responses. These results potentially help explain the level of immunocompetence observed in alemtuzumab-treated MS patients.
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA 01701, United States. michael.turner@genzyme.com
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Turner
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Lamorte
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chretien
authors.forename: Evis
authors.initials: E
authors.lastname: Havari
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Roberts
authors.forename: Johanne M
authors.initials: JM
authors.lastname: Kaplan
authors.forename: William M
authors.initials: WM
authors.lastname: Siders
mesh_terms: D056704:Adaptive Immunity / Q000235:genetics*; D000074323:Alemtuzumab; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000502:physiology*; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D000074301:CD52 Antigen; D002478:Cells, Cultured; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab
keywords: Alemtuzumab; CD52; Immune status; Multiple sclerosis